These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 16391836)

  • 41. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
    Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
    Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant Acinetobacter baumannii bacteraemia.
    Leshkasheli L; Kutateladze M; Balarjishvili N; Bolkvadze D; Save J; Oechslin F; Que YA; Resch G
    J Glob Antimicrob Resist; 2019 Dec; 19():255-261. PubMed ID: 31100499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The presence of extended spectrum beta-lactamase, KPC-type carbapenemase and plasmid-mediated AmpC beta-lactamase in E.coli and K.pneumoniae strains isolated from blood cultures].
    Baykal A; Cöplü N; Simşek H; Esen B; Gür D
    Mikrobiyol Bul; 2012 Apr; 46(2):159-69. PubMed ID: 22639305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-beta-lactamase-producing Escherichia coli among companion animals.
    Ewers C; Grobbel M; Stamm I; Kopp PA; Diehl I; Semmler T; Fruth A; Beutlich J; Guerra B; Wieler LH; Guenther S
    J Antimicrob Chemother; 2010 Apr; 65(4):651-60. PubMed ID: 20118165
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
    Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between Phage Lytic Spectra and Sequence Types in Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated in Japan.
    Yamamura S; Kitaoka K; Yamasaki Y; Fudeshima K; Miyanaga K; Tanji Y; Tsuneda S
    Jpn J Infect Dis; 2022 Nov; 75(6):623-626. PubMed ID: 35908876
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of tigecycline and molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from a university hospital in south-western Germany.
    Wienke M; Pfeifer Y; Weissgerber P; Marschal M; Autenrieth IB; Gröbner S
    Chemotherapy; 2012; 58(3):241-8. PubMed ID: 22832033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Picón E; Navarro MD; López-Cerero L; Pascual A;
    Clin Microbiol Infect; 2012 Sep; 18(9):894-900. PubMed ID: 21985560
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; Cueto Md; Gálvez J; Perea EJ; Pascual A
    Clin Microbiol Infect; 2008 Feb; 14(2):180-3. PubMed ID: 18005358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Efficacy of Isolated Bacteriophages from Pig Farms against ESBL/AmpC-Producing
    Skaradzińska A; Śliwka P; Kuźmińska-Bajor M; Skaradziński G; Rząsa A; Friese A; Roschanski N; Murugaiyan J; Roesler UH
    Front Microbiol; 2017; 8():530. PubMed ID: 28405193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia.
    Memon JI; Rehmani RS; Ahmed MU; Elgendy AM; Nizami IY
    Saudi Med J; 2009 Jun; 30(6):803-8. PubMed ID: 19526164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
    Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
    Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
    Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
    J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic evolution and clinical impact in extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Chong Y; Ito Y; Kamimura T
    Infect Genet Evol; 2011 Oct; 11(7):1499-504. PubMed ID: 21689785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of extended-spectrum β-lactamase-producing multidrug-resistant Escherichia coli among isolates from community-acquired infections and in silico structural modeling of an ESBL protein.
    Rajapandiyan K; Shanthi S; Vijayalakshmi P; Daisy P; Murugan M; Ranjitsingh AJ
    Microb Drug Resist; 2014 Apr; 20(2):170-6. PubMed ID: 24228708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.